Evidence Trace, complete trial record

In plain terms

In plain terms: PectaSol Modified Citrus Pectin (MCP) has not yet been tested in a human trial designed to measure the outcome relevant here. The available human research does not yet answer the question.

PectaSol Modified Citrus Pectin (MCP)

D Not shown: no human trial shows benefit

Route 1 — no qualifying human trial has been conducted

Category Supplements

Evidence Single-arm Phase II studies for the prostate use; two null placebo-controlled trials in other uses

Reviewed October 2026

PMIDs 31683865 · 14663471 · 22532035 · 34959847 · 33532663 · 31872160 · 37630724

The endpoint this grade is based on: Surrogate biomarker endpoint, PSA kinetics in biochemically relapsed prostate cancer, in two single-arm Phase II studies without a control group (D Route 1). The two placebo-controlled trials of the product, in hypertension with raised galectin-3 and in knee osteoarthritis, were both null (D Route 2). Metal-binding claims rest on uncontrolled studies by the product's developer and carry no letter.

The evidence as the record states it

Evidence record

PMID 31683865 PMID 14663471 PMID 22532035 PMID 34959847 PMID 33532663 PMID 31872160 PMID 37630724

Guess et al. (Prostate Cancer Prostatic Dis, 2003; PMID 14663471): single-arm study, 13 men with rising PSA after local treatment, 10 evaluated; PSA doubling time lengthened in 7 of 10 over 12 months, compared with each man's own earlier course. Keizman et al. (Nutrients, 2021; PMID 34959847): single-arm Phase II study, 59 men with non-metastatic biochemically relapsed prostate cancer, PectaSol 4.8 g three times daily; 78 percent without PSA progression at six months, a figure with no control group behind it, in a population where PSA can remain stable for long periods without treatment. Keizman et al. (Nutrients, 2023; PMID 37630724): the 18-month extension, reporting only the 39 men who continued after responding at six months; 85 percent with a durable response among that selected group, sponsored by the maker. Neither study had a control group. Eliaz et al. (Nutrients, 2019; PMID 31683865) is a review by the product's developer, background only; Jiang et al. (Integr Cancer Ther, 2013; PMID 22532035) is cell work on modified citrus pectin combined with two polybotanical compounds, mechanism only and not evidence for the pectin alone. Two placebo-controlled trials of the manufacturer's product in other uses were null: Lau et al. (JACC Basic Transl Sci, 2021; PMID 33532663), NIH-funded, 68 adults with hypertension and raised galectin-3, 4.8 g three times daily for 6 months against placebo, collagen markers unchanged; and Andrews et al. (Contemp Clin Trials Commun, 2020; PMID 31872160), 50 patients with knee osteoarthritis, 4 g twice daily for 12 weeks against placebo, no difference on WOMAC, SF-36 or RAPID3 and no change in serum galectin-3; neither is indexed in PubMed as a randomized trial, which is why the record's search did not return them; the manufacturer supplied the product in both and sponsored the Keizman prostate study, whose co-author Isaac Eliaz is the developer of the sponsoring company and the sole author of the 2019 review cited; funding of the Guess 2003 (PMID 14663471) study is not stated in its indexed record. Grade D, Route 1 for the prostate use: no randomized trial in prostate cancer. Single-arm PSA kinetics cannot carry a letter above D under EBL's rule.

PMID 31683865 PMID 14663471 PMID 22532035 PMID 34959847 PMID 33532663 PMID 31872160 PMID 37630724

Evidence by specific use

PSA kinetics in non-metastatic biochemically relapsed prostate cancer

Grade D

Guess et al. (2003; PMID 14663471) and Keizman et al. (2021 and 2023; PMID 34959847, PMID 37630724) are single-arm studies without a control group, the later two sponsored by the maker with its developer as co-author. PSA doubling time and PSA stability can change without treatment in this population, so uncontrolled figures cannot carry a letter. No randomized trial in prostate cancer exists: D on Route 1.

PMID 14663471 PMID 34959847 PMID 37630724

Collagen turnover and cardiac remodeling markers in hypertension with raised galectin-3

Grade D

Lau et al. (JACC Basic Transl Sci, 2021; PMID 33532663): the one placebo-controlled trial in cardiovascular use; galectin-3 inhibition with the pectin did not change collagen markers. Tested and no benefit, one trial: D on Route 2.

PMID 33532663

Knee osteoarthritis symptoms

Grade D

Andrews et al. (Contemp Clin Trials Commun, 2020; PMID 31872160): 12 weeks of the pectin did not improve disease burden against placebo and did not change galectin-3. Tested and no benefit, one small trial: D on Route 2.

PMID 31872160

Animal lifespan data and mechanistic plausibility are excluded from EBL grades by rule. They inform the scientific rationale but do not carry the letter.

Why Grade D Route 1 and not Grade C

Grade D Route 1 applies when no qualifying human randomized trial has tested this compound or intervention against the relevant endpoint. Absence confirmed: ("modified citrus pectin"[tiab] OR PectaSol[tiab]) AND randomized controlled trial[pt] (PubMed, October 2026)

The first qualifying human RCT with a meaningful endpoint would move this to Grade C or higher, depending on what it shows.

What this grade covers and what it does not

Grade D. For the prostate use the record grades, no randomized trial exists: Guess 2003 (PMID 14663471) and Keizman 2021 and 2023 (PMID 34959847, PMID 37630724) are single-arm Phase II studies without a control group, the later two sponsored by the maker, whose developer is a co-author; D on Route 1 for that use. The product has been tested in two placebo-controlled trials in other uses and failed both: collagen markers in hypertension with raised galectin-3 (Lau et al., 2021; PMID 33532663) and knee osteoarthritis symptoms (Andrews et al., 2020; PMID 31872160), each D on Route 2 on its own row. WHAT THIS GRADE DOES NOT COVER: metal binding, which rests on uncontrolled studies by the developer and carries no letter; galectin-3 lowering as an outcome, which no trial has linked to a clinical change; and generic modified citrus pectin products, which differ in molecular weight and were not the tested material.

What would move this grade

The first qualifying randomized controlled trial in humans, testing this intervention against a meaningful aging-relevant endpoint, would initiate grading. Depending on the result, it could land at any grade from A to D.

How to track whether this is working For prostate-cancer use, PSA kinetics should be managed in the oncology context because the human PectaSol studies used PSA/PSA-doubling-time endpoints. Galectin-3 can be measured, but the prostate studies did not establish it as a validated standalone treatment-response marker.